Alpha-Lipoic Acid for Blood Sugar and Diabetic Neuropathy
Context
These are modest effects – comparable to chromium, smaller than berberine. ALA is not a primary blood sugar intervention; it’s an adjunct.
Diabetic Neuropathy
This is where ALA’s evidence is strongest – and where its reputation was built.
Key Trials
- ALADIN Trial (1995): 328 type 2 diabetics with peripheral neuropathy. 600 mg IV ALA/day for 3 weeks significantly improved neuropathy symptoms vs. placebo.
- SYDNEY Trial (2003): 120 patients, 600 mg IV/day for 5 days. Significant symptom improvement.
- SYDNEY 2 (2006): Oral ALA at 600, 1,200, and 1,800 mg/day for 5 weeks. All doses improved neuropathy symptoms, but 600 mg had the best risk-benefit ratio.
- NATHAN 1 (2011): 460 patients, 600 mg oral ALA/day for 4 years. Improved neuropathy impairment scores but not symptoms. Mixed interpretation.
Honest Assessment
IV ALA at 600 mg/day consistently shows benefits for neuropathy symptoms. Oral evidence is real but weaker – bioavailability is only ~30%, and long-term oral studies are less convincing than short-term IV ones.
R-ALA vs. Racemic ALA
ALA exists in two mirror-image forms: R-ALA (naturally occurring, bioactive) and S-ALA (synthetic byproduct). Most supplements sell racemic ALA (50/50 mix). R-ALA supplements claim better bioavailability, and there’s some pharmacokinetic evidence supporting this, but:
- R-ALA is less stable and more expensive
- Clinical trials overwhelmingly used racemic ALA
- The practical difference in outcomes is unclear
Honest take: If R-ALA is affordable for you, it’s theoretically preferable. But the clinical evidence base was built on racemic ALA, which clearly works.
Dosing
- Blood sugar support: 300-600 mg/day oral
- Neuropathy support: 600 mg/day oral (ideal: with medical supervision)
- Take on empty stomach for better absorption
Safety
- GI discomfort at higher doses (>600 mg)
- Hypoglycemia risk when combined with diabetes medications
- Rare: skin rash, headache
- Theoretical concern: may lower thyroid hormone levels (limited evidence)
Who Should Consider ALA
- People with type 2 diabetes and neuropathy symptoms (strongest use case)
- People with prediabetes looking for gentle adjunctive support
- People already on berberine or metformin who want additional antioxidant support
Who Probably Doesn’t Need It
- People without insulin resistance or neuropathy
- People looking for dramatic blood sugar effects (this isn’t that)
For the full blood sugar supplement breakdown, see our complete guide.
Frequently Asked Questions
Does alpha-lipoic acid lower blood sugar?
Modest blood sugar-lowering effects have been documented in several small RCTs in people with type 2 diabetes or prediabetes. ALA activates GLUT4 translocation, improving cellular glucose uptake. The effect is real but modest and less consistent than berberine or metformin.
What is the best form and dose of alpha-lipoic acid?
R-ALA is the naturally occurring, more biologically active form. The synthetic racemic mixture (R/S-ALA) is what most supplements contain. R-ALA at 100-300 mg has effects roughly equivalent to 300-600 mg of the racemic form. All forms should be taken on an empty stomach.
Can alpha-lipoic acid help with nerve pain from diabetes?
Intravenous ALA has the strongest evidence, showing meaningful improvement in pain, burning, and numbness in diabetic peripheral neuropathy across several European clinical trials. Oral ALA also shows benefit but with smaller effect sizes. This is one of the areas where ALA has the most credible clinical evidence.
Is alpha-lipoic acid safe for people with diabetes who take medication?
ALA can add to the blood sugar-lowering effect of diabetes medications, potentially causing hypoglycemia. People on insulin or oral hypoglycemics should monitor blood sugar more closely and discuss ALA supplementation with their physician. For more detail, see our related guide on alpha lipoic acid for blood sugar.
References
- The protective effect of alpha-lipoic acid on the expression of collagen IV, renal function, and oxidative stress induced by diazinon in the renal parenchyma of rat. Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia. 2020. PMID: 33565443.
- Ziegler D et al. (1995) ALADIN trial. Diabetologia.
- Ziegler D et al. (2006) SYDNEY 2 trial. Diabetes Care.
- Ziegler D et al. (2011) NATHAN 1 trial. Diabetes Care.
- Wang Q, Wang X (2023). The Effect of Plant-Derived Low-Ratio Linoleic Acid/α-Linolenic Acid on Markers of Glucose Controls: A Systematic Review and Meta-Analysis. International journal of molecular sciences. PMID: 37762686.
Related Articles
- Best Supplements for Blood Pressure in 2026: What the Evidence Actually Supports
- Berberine vs Metformin: What the Evidence Actually Shows for Blood Sugar Support
- Berberine and Blood Sugar: What the Clinical Evidence Actually Shows
- Fenugreek and Bitter Melon for Blood Sugar: Traditional Remedies With Mixed Evidence
Leave a Reply